PLASMA RICH IN GROWTH FACTORS IN FOREFOOT RECONSTRUCTION SURGERY

Abo Zaalan Wessam1, Levon Gagikovich Makinyan2, Nikolai Vasilivich Zagorodniy3, Arsen Yusufovich Khubiev4, Abdul Basith Shahul Hameed5

1 Department of Traumatology and Orthopedics, Peoples’ Friendship University of Russia, Moscow
2 Department of Traumatology and Orthopedics, Peoples’ Friendship University of Russia, Moscow; Head of Orthopedic Department № 2 in City Clinical hospital № 13, Moscow; Member of AOFAS
3 Department of Traumatology and Orthopedics, Doctor of Medical Science, Laureate of the Russian Government Award, Honored Scientist of the Russian Federation, Corresponding Member of the Russian Academy of Sciences.
4 North Caucasian Federal Scientific Clinical Center of the Federal Medical and Biological Agency of Russia, 101 Clinical Hospital, Lermontov, Russia
5 Department of Traumatology and Orthopedics, Peoples’ Friendship University of Russia, Moscow

ABSTRACT
Plasma rich in growth factors (PRGF) is a successful therapy in various sectors of medicines in the present decade. Its effectiveness in forefoot surgery is still unknown. The aim of our study is to analyze the outcomes of forefoot surgeries with the infiltration of PRGF. One hundred and eighty patients were divided into 2 groups. The first group included 90 patients where only forefoot reconstruction was performed, whereas, in the second group PRGF was added. Scarf and Wilson osteotomies were performed for hallux valgus and tailor’s bunion respectively. Clinical and radiological outcomes were monitored in both groups pre and postoperatively. The mean postoperative AOFAS scores were 67.82 (range: 32 – 82) and the mean postoperative Foot Function Index (FFI) was 0.51 (range: 0.23 to 0.63) in the PRGF group. Ninety percent (162/180 feet) reported early pain relief, improved cosmetic appearance and improved footwear comfort. The mean hallux valgus angles improved from 30° to 15°, 1st IMA from 15° to 8° and 4-5 IMA from a mean of 11° to 7° in both groups. Four feet had non-union of the Scarf osteotomy and three of them were re-operated. PRGF stimulates cell viability and proliferation and enhances the surgical treatment of forefoot deformities by reducing postoperative pain, edema, and rehabilitation period and improves cosmesis and comfort.

Keywords: PRGF, Hallux valgus, Tailor Bunion, Scarf osteotomy, Wilson osteotomy, Foot Function Index.

INTRODUCTION
Forefoot reconstruction is an ultimate treatment option for painful forefoot deformities especially when the medications and therapy fail [1]. Scarf osteotomy is a common surgical method to correct moderate to severe hallux valgus deformities [2]. After the initial description by Barouk and Weil [3, 1], several papers presenting good outcomes with this technique have been published [4, 5]. However, the probability of recurrence is a common issue and the postoperative rehabilitation period remains longer [2, 6]. Complex forefoot structure can also explain these results. Special shoes are prescribed in the postoperative period (Barouk) during 6 weeks after surgery to avoid weight bearing on the forefoot. Patients also go under RICE (Rest, Ice, Compression and Elevation) regimens. The complete recovery took between 3 to 4 months with several restrictions. Postoperative pain and edema are unpleasant for some patients. For those reasons, there is an urge to search for another alternative to assure better outcomes (reducing rehabilitation time, fast recovery and better cosmetic results).

The use of plasma rich in growth factors (PRGF) is reported as a good treatment to improve pain,
stiffness and functional capacity in articular surfaces, as well as improving soft tissue healing [7, 8]. A recent randomized controlled trial showed that PRGF is safe and significantly superior to hyaluronic acid (HA) in patients with symptomatic knee osteoarthritis (OA) [9]. In 2010, Saegusa and coauthors reported improvement in function and quality of life after intra-articular infiltration of PRGF in patients with OA of the knee [9]. In 2015, Seijas and coauthors documented improvement in pain, stiffness and functional capacity in patients after arthroscopic debridement of the acetabular rim and femoral neck for femoroacetabular impingement and injection of PRGF in OA hips [10]. Currently, PRGF administration is quite common. However, clear guidelines defining indication criteria are missing. The purpose of this study is to analyze the clinical and radiological outcomes in forefoot reconstruction with the PRGF administration.

MATERIALS AND METHODS

Between October 2018 and October 2021 a study was carried out on 180 patients. Inclusion criteria of patients in our study were based on the forefoot deformities, especially Hallux valgus (HV) and Tailor’s bunion. They were equally divided into 2 groups. The 1st group included 90 patients (90 feet) who underwent Scarf and Wilson osteotomies in the forefoot. The 2nd group had 90 patients (90 feet) whose Scarf and Wilson osteotomies were performed and intraoperative administration of PRGF was carried out. Administration of PRGF has been approved by committee of Peoples’ Friendship University of Russia, Moscow for research purpose to understand its effect in foot surgeries. Interventions were performed in just one side at a time. Patients were admitted to the hospital only after all the medical conclusions stating no signs of contraindications for surgery. The HV angle, the first and second intermetatarsal angles (IMA), the fourth and fifth IMA, the fifth toe metatarsophalangeal angle, the fifth metatarsal head width, and the fifth metatarsal lateral angulation angle were measured on the X-ray (Fig. 1). Grading of the tailor’s bunion was made using Fallat’s classification (Fig. 2). Only patients with Hallux valgus angle (HVA) between 20 and 30 degrees and type III deformity according to Fallat’s classification were included in the study. All patients were given written informed consent. Patients underwent clinical and radiological examinations before and after the surgery followed by 3 years of follow up.

Figure 1: Preoperative weightbearing AP radiograph demonstrating forefoot deformities calculations

Figure 2: Fallat’s classification. Type 1. Increased width of the MT head. Type 2. Deviation of the 5th MT. Type 3. Increased 4th & 5th IMA [11].
Plasma Rich in Growth Factors (PRGF)

Thirty-six milliliters of blood were collected from the veins of all patients. Collected blood was shifted to four vacutainer tubes, each containing blood anticoagulant of 5 milliliters in quantity. Followed by eight minutes of centrifugation at 460 g allowing it to separate various blood phases (PRGF® System III, BTI Biotechnology Institute®, Spain). The 2 milliliters rich plasma fragments present directly on top of the buffy coat were extracted from each tube and shifted to a sterile vacutainer tube. PRGF activator (10% calcium chloride) was added to the liquid PRGF (50 microliters per milliliter of PRGF) to begin clotting and stimulate platelets to release growth factors. This was used before the wound closure (Fig. 3).

Figure 3: Preparation of PRGF

SURGICAL PROCEDURE

Scarf osteotomy of 1st MT bone

Under the spinal anesthesia, patient in supine position in the operating table. Tourniquet applied in the lower third of the leg. A dorsomedial incision with a length of 5 cm performed, soft tissues are dissected along the medial side of the foot. Capsule of the first metatarsophalangeal joint (MTPJ) opened linearly. Bone cartilaginous exostosis was resected with an oscillator saw, followed by Scarf osteotomy of the first metatarsal (MT) bone. The osteotomy was Z-shaped with the distal lever on the dorsal aspect and the proximal lever on the plantar aspect with an angle of 45°. The distal fragment was shifted laterally with a slight varus rotation to realign the joint line. Bone/cartilaginous exostosis was resected using an oscillator saw. Fixation was achieved with 2 screws (2.5 or 3.0 mm—FRS-Screw) [Fusion and Reconstruction System], at least one of them was positioned bicortically. The prominent medial aspect of the metatarsal shaft was resected with the saw. This piece of bone was grafted to the medial side of the metatarsal between distal and proximal lever. The tendon sheet of the extensor hallucis was kept intact. The transverse intermetatarsal ligament was released and capsulorraphy was performed to obtain normal position of the Hallux (fig. 4).

Figure 4: Scarf osteotomy [12]

Wilson osteotomy of 5th MT bone

A 2 cm longitudinal incision along the outer surface of the 5th MTPJ of the foot performed. Soft tissues are dissected and capsule of the 5th MTPJ opened linearly. Wilson (oblique) osteotomy of the 5th MT bone performed followed by a medial shift in the distal fragment with a slight varus rotation to realign the joint line. Bone/cartilaginous exostosis was resected using an oscillator saw. Fixation was achieved with 1 screw (2.5 or 3.0 mm—FRS-Screw). PRGF - was administered intra- and extra-articular and over the soft tissues before the wound closure in the 2nd group but not used in the first group.

All patients were mobilized on 2nd day subsequently using specific non-weightbearing orthopedic (Barouk) shoes. They were discharged from the hospital once swelling subsided. During dressing neither signs of bleeding nor any pus formation were noticed. Local and body temperature were evaluated. All the recommendations to be followed carefully were explained and given in written form. Patients were evaluated regularly in the outpatient clinic at 6 weeks, 3 months, 6 months, 1 year, 2 years and 3 years postoperatively. American Orthopaedic Foot and Ankle Society (AOFAS), Foot Function Index (FFI) and radiological findings were evaluated.
Statistical Analysis

With the help of statistics package SPSS version 23.0 (IBM Corp., Armonk, NY) statistical analysis was performed. Descriptive statistics values are indicated by standard deviation (SD), frequencies and percentages for nominal data. The Kendall rank correlation coefficient ($r_\phi$) was utilized to evaluate the relation between pain, recurrence and satisfaction. Based on accepted standards, statistical significance was accepted to a 2-tailed $P$ value of 0.05.

RESULTS

The study included 176 female patients and 4 male patients, indicating higher frequency of incidence in females. The average age of the patients was 40 years (28 - 48). The above figure describes pre and post-op radiographs demonstrating hallux valgus and Tailor’s bunion and its correction by Scarf and Wilson osteotomy. Here, intraoperative infiltration of PRGF has taken place.

![Pre and postoperative radiograph of Patient A with PRGF](image)

Table 1: Follow-up AOFAS scores of 180 patients

<table>
<thead>
<tr>
<th>Category</th>
<th>Pre-op Mean score (1 to 10)</th>
<th>Post-op Mean score (1 to 10)</th>
<th>Pre-op Mean score (1 to 10)</th>
<th>Post-op Mean score (1 to 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(1st Group)</td>
<td>(2nd Group)</td>
<td>(1st Group)</td>
<td>(2nd Group)</td>
</tr>
<tr>
<td>Pain (VAS score)</td>
<td>8.7 (6 to 9)</td>
<td>2.6 (1 to 3)</td>
<td>8.8 (6 to 9)</td>
<td>2.1 (1 to 3)</td>
</tr>
<tr>
<td>Mobility</td>
<td>3.4 (3 to 5)</td>
<td>5.6 (5 to 7)</td>
<td>3.4 (3 to 5)</td>
<td>6.0 (5 to 7)</td>
</tr>
<tr>
<td>Footwear tolerance</td>
<td>3.4 (2 to 5)</td>
<td>7.2 (6 to 8)</td>
<td>3.4 (2 to 5)</td>
<td>7.6 (6 to 8)</td>
</tr>
<tr>
<td>Cosmetic appearance</td>
<td>1.8 (1 to 2)</td>
<td>8.3 (7 to 9)</td>
<td>1.8 (1 to 2)</td>
<td>8.9 (7 to 9)</td>
</tr>
</tbody>
</table>

Table 2: Anterior-posterior and lateral radiographs pre & postoperatively

<table>
<thead>
<tr>
<th>Time period</th>
<th>1st Group</th>
<th>2nd Group (PRGF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before Surgery</td>
<td>Hallux valgus, Tailor Deformity</td>
<td>Hallux valgus, Tailor Deformity</td>
</tr>
<tr>
<td>Next day of Surgery</td>
<td>Corrected to normal anatomy</td>
<td>Corrected to normal anatomy</td>
</tr>
<tr>
<td>After 6 weeks</td>
<td>Signs of endosteal callus</td>
<td>Periosteal corn</td>
</tr>
<tr>
<td>After 3 months</td>
<td>Muff-like periosteal callus</td>
<td>Much larger periosteal callus</td>
</tr>
<tr>
<td>After 6 months</td>
<td>Periosteal clutch and signs of bone consolidation</td>
<td>Bone consolidation</td>
</tr>
<tr>
<td>After 12 months (fig. 6)</td>
<td>Bone fusion</td>
<td>Bone fusion with disappearance of the fracture line</td>
</tr>
<tr>
<td>After 24 months</td>
<td>Delayed complete reconstruction of the callus</td>
<td>Complete reconstruction of the callus</td>
</tr>
</tbody>
</table>
Postoperative Period: (Tables 1-4)

1\textsuperscript{st} group

Patients reported presence of pain until postoperative swelling began to subside. NSAIDs were taken on indications. After a week, patients noticed decrease of edema. All patients had intradermal sutures and thus prolonged edema led to wound healing problems. Patients were allowed walk: changing dressing was done by the second or third day, patients were allowed to walk. Patients were allowed to walk on the 2\textsuperscript{nd} day with Barouk shoes but they reported significant difficulties in walking due to pain. They could walk for a distance of 5 meters for 5 minutes 3 times per day at the 1\textsuperscript{st} week. As time progresses, gradual increase in walking distances was noticed. Sutures were removed on 3\textsuperscript{rd} week. Patients were allowed to walk with Barouk shoes until 6 weeks postoperatively. Customized insoles were made on the 7\textsuperscript{th} week.

2\textsuperscript{nd} group

Patients in the PRGF group had the earlier relief from pain, edema and increased walking ability compared to the 1\textsuperscript{st} group. The sutures were removed on 15-17 days. Patients used Barouk shoes until 4 weeks and customized insoles were made on 5\textsuperscript{th} week. There were no local or superficial infections, allergic reactions, or any other complications related to intra and extra-articular PRGF infiltration during the procedure.

At a mean follow up of 3 years, 73.3% patients had no pain or only mild pain. Seven percent patients responded as having moderate pain, and 7% patients had severe pain. Two patients had a wound breakdown, which healed with local wound care in 4 weeks. The VAS results for pain after PRGF show a higher percentage of improved patients (73.4\%) than without PRGF (56\%).

The AOFAS and FFI results in the PRGF group were more significant (P < 0.0001) than the results in the group without PRGF (P < 0.041). The average post-operative AOFAS score was 67.82 (range: 32 to 82), and the mean post-operative Foot Function Index (FFI) was 0.51 (range: 0.23 to 0.63) in PRGF group (Table 4).

In the radiological assessment, ninety percent of feet (162/180) had evidence of good outcome. At the time of most recent follow-up the Hallux valgus angle (HVA) was corrected from a mean of 30° (pre-operative) to 15° (post-operative), 1\textsuperscript{st} inter-metatarsal angle (IMA) was corrected from a mean of 15° (pre-operative) to 8° (post-operative) and 4-5 IMA was corrected from a mean of 11° (pre-operative) to 7° (post-operative) in both groups. Four feet had non-union of the Scarf osteotomy and three among them were re-operated.

On X-ray examination there was a significant difference in the PRGF group (p < 0.001) (Table 4). A regular follow-up radiographs in our study depicts that periosteal corn appeared after 6 weeks. After 3 months, the formation of a much larger periosteal callus of a cloud-like structure was observed. After 6 months, the consolidation of fragments was determined on radiographs. After 1 year, bone fusion occurred on radiographs of both groups. But in cases of PRGF, a decrease in the size of the muff-like bone callus occurred along with the disappearance of the
osteotomy line. After 2 years, the complete reverse development of the callus is completed.

Table 4: Mean variables with p value.

<table>
<thead>
<tr>
<th>Group</th>
<th>Mean AOFAS</th>
<th>Mean FFI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>65.0</td>
<td>0.49</td>
<td>&lt;0.041</td>
</tr>
<tr>
<td>II (PRGF)</td>
<td>67.82</td>
<td>0.51</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

DISCUSSION

Wound healing is a complex biological process that consists of hemostasis, inflammation, proliferation and remodeling [13]. Growth factors play a vital role in regulating cellular processes such as mitogenesis, chemotaxis, cell differentiation and metabolism. Platelets enhance growth factors distribution in early stages of wound healing [14]. In 1999, for the first time Anitua proposed Plasma rich in growth factors (PRGF) technology, an innovation in medical therapy [15]. PRGF is a subtype of P-PRP (pure platelet-rich plasma). It is a supernatant enriched in plasma and platelet-derived morphogens, proteins and growth factors. PRGF represents a complex pool of active mediators that may stimulate and accelerate tissue regeneration, which is generally safe to use and inexpensive to obtain. “PRGF” relates 100% autologous and biocompatible formulations formed by a single-step process of centrifugation with calcium chloride and sodium citrate as activator and anticoagulant respectively. PRGF includes moderate platelet concentration but no leukocytes to avoid the proinflammatory effects of proteases and acid hydrolases in white blood cells [16, 17]. Platelet-derived Growth Factors obtained from autologous blood are proteins with the capacity to stimulate chondrocytes to regenerate cartilage. PRGF-treated chondrocytes showed markedly increased synthesis of proteoglycans and collagen. PRGFs is an excellent mode for growth factors (GFs), especially PDGF and TGFβ. GFs released from activated platelets initiate and modulate wound healing in both soft and hard tissue [18]. A recent strategy to promote the healing cascade is to apply a concentrate of autologous platelets obtained from plasma and containing GFs (PRGF) to the injury [19]. Its autologous nature gives it a significant advantage in tissue engineering applications which can be improved with the addition of adjuncts that increase the proliferation and differentiation of progenitor or stem cells [20]. The effectiveness of autologous bone marrow stromal cell therapy was shown in articular cartilage defect repair [21, 22], restoring knee stability and function in acute incomplete anterior cruciate ligament lesions in athletes [23]. The results obtained in a cell culture experiment devised in mesenchymal stem cells (MSCs) confirm that PRP (platelet-rich plasma) enhances MSC proliferation and suggest that PRP causes chondrogenic differentiation of MSC in vitro [20] providing a promising alternative to surgery by promoting safe and natural healing [24]. The therapeutic use of platelets in a fibrin clot has a positive influence in clinical situations requiring rapid healing [25]. It has been safely used and documented in the last 20 years in many fields, including [24]: orthopedics, sports medicine, odontology, periodontal, cosmetic medicine, plastic and cosmetic surgery and maxillofacial surgery, amongst others. The efficacy of this treatment resides in the continuous, local release of a wide range of GFs and proteins necessary for healing in a process that imitates physiological tissue repair [24, 26].

In an experimental study in an animal model, Soler [27] reported that administration of intra-articular PRGF is effective for repair of full-thickness cartilage injuries in rabbit and reduces healing time of these injuries when compared with conventional treatments, such as chondroitin sulphate and HA.

Intra-articular infiltration of autologous PRGF was well tolerated over the entire study period. The only secondary effects were local and infrequent at the injection site. A systematic review of 20 clinical trials investigating the efficacy and safety of PRGF in healing and regenerating hard and soft tissue in medical and surgical procedures concluded that there were no complications related to the use of PRGF [28]. Safety is provided by the anti-bactericidal secretion of proteins by platelets which participate directly in the elimination of bacteria during sepsis. Platelets ability to reduce pain is due to a suppression of the inflammatory phase and a relatively low level of interleukins [25, 29]. It has been reported that the cells remain phenotypically stable in the presence of PRGF [30]. The safety of PRGF and the low incidence of adverse effects [24] make it an appropriate treatment for patients with foot deformities, particularly the elderly, those intolerant to NSAIDs and those in whom NSAIDs are contraindicated. It could also be used to treat other joints, although the effect and outcome of this approach on the evolution of foot should be investigated.

The search for safe and effective therapeutic and co-adjuvant treatment for such a common condition generates considerable interest; PRGF application has been showing promising results [31]. This study shows that intra-operative infiltration of PRGF in forefoot according to the established protocol is safe, tolerable and effective, resulting in a reduction in pain at short term. The mean interval between the two questionnaires was 191 days (range 160–200). It is not surprising that the reduction in pain was associated with a functional improvement, as
documented with the AOFAS and FFI. PRGF could balance angiogenesis and restore HA concentration in the joint [32]. The PRGF technique uses platelets as bearers of GFs and other proteins that are important for bone biology. The release of these proteins from the platelet alfa granules, and the concentration and deposit at the site of injury can be controlled. Thus, the lesion is exposed to a physiologic concentration of proteins that accelerates and favors the process of repair and regeneration [26]. Thus, we can say that intraoperative infiltration of autologous PRGF seems to be a safe, effective treatment for forefoot deformity, with no associated systemic complications.

CONCLUSIONS
A 3 year follow-up illustrates compelling prolonged outcomes after the surgery. The results obtained indicate that infiltration of autologous PRGF during forefoot reconstruction surgery has local, effective and temporal effects reducing pain and restoring function, without provoking local or systemic adverse events. Better radiological outcomes are reported in the PRGF group. The simplicity of PRGF use makes it an attractive option for surgeons and researchers. PRGF had a solid stimulatory effect on cell viability and proliferation. Overall, more than 80% of the patients remained satisfied with the outcome. Thus, PRGF favors the surgical treatment by minimizing the rehabilitation period, postoperative pain, and edema and enhances better cosmesis. Nonetheless, further study and clinical trials are needed to confirm the results observed.

Ethical clearance: All patients were given written informed consent. No animal experiments were done. It has been approved by committee of Peoples’ Friendship University of Russia, Moscow.

Acknowledgements
All authors have contributed in manuscript writing and hold full responsibility for the content mentioned.

Conflicts of Interest and Source of Funding: No conflicts were declared. Disclosure of Funding: No funding received for this work from any organizations.

REFERENCES


